A5202: A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZANAVIR

A5202：开放标签依非韦伦或阿扎那韦的 IIIB 期随机试验

• 批准号: 7604223
• 负责人: ROY M. GULICK
• 金额: $ 3.92万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604223
• 关键词: Atazanavir; Blinded; Computer Retrieval of Information on Scientific Projects Database; Daily; Funding; Grant; HIV-1; Infection; Institution; Label; Lamivudine; Phase; Randomized; Randomized Controlled Clinical Trials; Research; Research Personnel; Resources; Ritonavir; Safety; Source; Tenofovir; United States National Institutes of Health; Upper arm; abacavir; efavirenz; emtricitabine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5202 is a phase IIIB, randomized, four-arm study, comparing the efficacy, safety, and tolerability of open-lable ritonavir (RTV)-enhanced atazanavir (ATV) to efavirenze (EFV), in combination with either daily emtricitabine (FTC)/ tenofovir (TDF) or abacavir (ABC)/lamivudine (3TC) and of partially blinded ABC/3TC compared to FTC/TDF in combination with either RTV-enhanced ATV or EFV as initial therapy for HIV-1 infection.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 A5202 是一项 IIIB 期、随机、四组研究，比较开放标签利托那韦 (RTV) 增强型阿扎那韦 (ATV) 与依非韦伦 (EFV) 联合每日恩曲他滨 (FTC) 的疗效、安全性和耐受性/ 替诺福韦 (TDF) 或阿巴卡韦 (ABC)/拉米夫定 (3TC) 以及部分盲法 ABC/3TC 的比较FTC/TDF 与 RTV 增强型 ATV 或 EFV 联合作为 HIV-1 感染的初始治疗。